KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Tax Provisions: 2011-2024

Historic Tax Provisions for Vertex Pharmaceuticals (VRTX) over the last 14 years, with Dec 2024 value amounting to $784.1 million.

  • Vertex Pharmaceuticals' Tax Provisions rose 20.82% to $215.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $773.6 million, marking a year-over-year increase of 4.63%. This contributed to the annual value of $784.1 million for FY2024, which is 3.14% up from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Tax Provisions stood at $784.1 million for FY2024, which was up 3.14% from $760.2 million recorded in FY2023.
  • Over the past 5 years, Vertex Pharmaceuticals' Tax Provisions peaked at $910.4 million during FY2022, and registered a low of $388.3 million during FY2021.
  • Over the past 3 years, Vertex Pharmaceuticals' median Tax Provisions value was $784.1 million (recorded in 2024), while the average stood at $818.2 million.
  • In the last 5 years, Vertex Pharmaceuticals' Tax Provisions soared by 134.46% in 2022 and then decreased by 16.50% in 2023.
  • Over the past 5 years, Vertex Pharmaceuticals' Tax Provisions (Yearly) stood at $405.2 million in 2020, then declined by 4.17% to $388.3 million in 2021, then soared by 134.46% to $910.4 million in 2022, then declined by 16.50% to $760.2 million in 2023, then rose by 3.14% to $784.1 million in 2024.